Neuroscience

Articles and news from the latest research reports.

Posts tagged methylphenidate

216 notes

ADHD Drug May Help Preserve Our Self-Control Resources

Methylphenidate, also known as Ritalin, may prevent the depletion of self-control, according to research published in Psychological Science, a journal of the Association for Psychological Science.

image

Self-control can be difficult — sticking with a diet or trying to focus attention on a boring textbook are hard things to do. Considerable research suggests one potential explanation for this difficulty: Exerting self-control for a long period seems to “deplete” our ability to exert self-control effectively on subsequent tasks.

“It is as if self-control is a limited resource that ‘runs out’ if it is used too much,” says lead researcher Chandra Sripada of the University of Michigan. “If we could figure out the brain mechanisms that cause regulatory depletion, then maybe we could find a way to prevent it.”

Previous research has implicated the neurotransmitters dopamine and norepinephrine in regulatory processing. Sripada and University of Michigan collaborators Daniel Kessler and John Jonides decided to see whether manipulating levels of these transmitters might affect regulatory depletion.

The researchers tested 108 adult participants, all of whom took a drug capsule 60 minutes prior to testing. Half of the participants received a capsule that contained methylphenidate, a medication used to treat ADHD that increases brain dopamine and norepinephrine. The other half received a placebo capsule. The study was double-blind, so neither the participants nor the researchers knew at the time of testing who had received which capsule.

The participants then completed a computer-based task in which they were required to press a button when a word containing the letter e appeared on screen. Some were given modified instructions that asked them to refrain from pressing the button if the letter e was next to or one extra letter away from another vowel — this version of the task was designed to tax participants’ self-control.

All of the participants then completed a second computer task aimed at testing their ability to process competing information and exert regulatory control in order to make a correct response.

In line with the researchers’ hypotheses, participants who received the placebo and performed the taxing version of the first task showed greater variability in how quickly they responded in the second task, compared to those whose self-control hadn’t been depleted in the first task.

But for those participants who took the methylphenidate capsule, the first task didn’t have an effect on later performance — the methylphenidate seemed to counteract the self-regulatory depletion incurred by the harder version of the first task.

“These results indicate that depletion of self-control due to prior effort can be fully blocked pharmacologically,” says Sripada. “The task we give people to deplete their self-control is pretty cognitively demanding, so we were surprised at how effective methylphenidate was in blocking depletion of self-control.”

Sripada and colleagues suggest that methylphenidate may help to boost performance of the specific circuits in the brain’s prefrontal cortex that are normally compromised after sustained exertion of self-control.

This doesn’t mean, however, that those of us looking to boost our self-control should go out and get some Ritalin:

“Methylphenidate is a powerful psychotropic medicine that should only be taken with a prescription,” says Sripada. “We want to use this research to better understand the brain mechanisms that lead to depletion of self-control, and what interventions — pharmacological or behavioral — might prevent this.”

Filed under ADHD methylphenidate self-control cognitive control attention psychology neuroscience science

104 notes

Ritalin Shows Promise in Treating Addiction

A single dose of a commonly-prescribed attention deficit hyperactivity disorder (ADHD) drug helps improve brain function in cocaine addiction, according to an imaging study conducted by researchers from the Icahn School of Medicine at Mount Sinai. Methylphenidate (brand name Ritalin®) modified connectivity in certain brain circuits that underlie self-control and craving among cocaine-addicted individuals. The research is published in the current issue of JAMA Psychiatry, a JAMA network publication.

Previous research has shown that oral methylphenidate improved brain function in cocaine users performing specific cognitive tasks such as ignoring emotionally distracting words and resolving a cognitive conflict. Similar to cocaine, methylphenidate increases dopamine (and norepinephrine) activity in the brain, but, administered orally, takes longer to reach peak effect, consistent with a lower potential for abuse. By extending dopamine’s action, the drug enhances signaling to improve several cognitive functions, including information processing and attention.

“Orally administered methylphenidate increases dopamine in the brain, similar to cocaine, but without the strong addictive properties,” said Rita Goldstein, PhD, Professor of Psychiatry at Mount Sinai, who led the research while at Brookhaven National Laboratory (BNL) in New York. “We wanted to determine whether such substitutive properties, which are helpful in other replacement therapies such as using nicotine gum instead of smoking cigarettes or methadone instead of heroin, would play a role in enhancing brain connectivity between regions of potential importance for intervention in cocaine addiction.”

Anna Konova, a doctoral candidate at Stony Brook University, who was first author on this manuscript, added, ”Using fMRI, we found that methylphenidate did indeed have a beneficial impact on the connectivity between several brain centers associated with addiction.”

Dr. Goldstein and her team recruited 18 cocaine addicted individuals, who were randomized to receive an oral dose of methylphenidate or placebo. The researchers used functional magnetic resonance imaging (fMRI) to measure the strength of connectivity in particular brain circuits known to play a role in addiction before and during peak drug effects. They also assessed each subject’s severity of addiction to see if this had any bearing on the results.

Methylphenidate decreased connectivity between areas of the brain that have been strongly implicated in the formation of habits, including compulsive drug seeking and craving. The scans also showed that methylphenidate strengthened connectivity between several brain regions involved in regulating emotions and exerting control over behaviors—connections previously reported to be disrupted in cocaine addiction.

“The benefits of methylphenidate were present after only one dose, indicating that this drug has significant potential as a treatment add-on for addiction to cocaine and possibly other stimulants,” said Dr. Goldstein. “This is a preliminary study, but the findings are exciting and warrant further exploration, particularly in conjunction with cognitive behavioral therapy or cognitive remediation.”

(Source: newswise.com)

Filed under ritalin addiction ADHD dopamine methylphenidate cocaine addiction neuroscience science

166 notes

Patience reaps rewards
Brain imaging shows how prolonged treatment of a behavioral disorder restores a normal response to rewards
Attention-deficit/hyperactivity disorder (ADHD) is characterized by abnormal behavioral traits such as inattention, impulsivity and hyperactivity. It is also associated with impaired processing of reward in the brain, meaning that patients need much greater rewards to become motivated. One of the common treatments for ADHD, methylphenidate (MPH), is known to improve reward processing in the short term, but the long-term effects have remained unclear.
Kei Mizuno from the RIKEN Center for Life Science Technologies, in collaboration with colleagues from several other Japanese research institutions, has now demonstrated that prolonged treatment with MPH brings about stable changes in brain activity that improve reward processing with a commensurate improvement in ADHD symptoms.
ADHD is thought to affect up to 5% of children worldwide, and about half of those will go on to experience symptoms of the disorder into adulthood. MPH treats the disorder by increasing the levels of the brain chemical dopamine, which is involved in reward processing.
To understand the effect of MPH on ADHD symptoms and specifically reward processing over the longer term, the researchers studied the reward response behavior of ADHD and healthy patients—all children or adolescents—before and after treatment with osmotic release oral system (OROS) MPH. They used functional magnetic resonance imaging (fMRI) to measure brain activity during a task that saw participants rewarded with payment, but in two different scenarios: a high and a low monetary reward condition.
“In the high monetary reward condition, participants earned higher than the expected reward; whereas in the low monetary condition, participants earned an average reward that was consistently lower than expected,” says Mizuno.
The brain images showed that before treatment with OROS-MPH, ADHD patients had lower than normal sensitivity to reward, as demonstrated by their abnormally low brain activity in two parts of the brain associated with reward processing—the nucleus accumbens and the thalamus—during testing under the low monetary reward scenario.
However, after three months of treatment with OROS-MPH, there was no difference in the activity of these brain areas in ADHD patients compared with the healthy controls under any of the reward conditions. Their sensitivity to reward had returned to normal, and the patients’ other ADHD symptoms also showed improvement.
Mizuno says that this study goes further than previous work. “We knew that acute MPH treatment improves reward processing in ADHD,” he explains. “Now we’ve revealed that decreased reward sensitivity and ADHD symptoms are improved by treatment for three months.”

Patience reaps rewards

Brain imaging shows how prolonged treatment of a behavioral disorder restores a normal response to rewards

Attention-deficit/hyperactivity disorder (ADHD) is characterized by abnormal behavioral traits such as inattention, impulsivity and hyperactivity. It is also associated with impaired processing of reward in the brain, meaning that patients need much greater rewards to become motivated. One of the common treatments for ADHD, methylphenidate (MPH), is known to improve reward processing in the short term, but the long-term effects have remained unclear.

Kei Mizuno from the RIKEN Center for Life Science Technologies, in collaboration with colleagues from several other Japanese research institutions, has now demonstrated that prolonged treatment with MPH brings about stable changes in brain activity that improve reward processing with a commensurate improvement in ADHD symptoms.

ADHD is thought to affect up to 5% of children worldwide, and about half of those will go on to experience symptoms of the disorder into adulthood. MPH treats the disorder by increasing the levels of the brain chemical dopamine, which is involved in reward processing.

To understand the effect of MPH on ADHD symptoms and specifically reward processing over the longer term, the researchers studied the reward response behavior of ADHD and healthy patients—all children or adolescents—before and after treatment with osmotic release oral system (OROS) MPH. They used functional magnetic resonance imaging (fMRI) to measure brain activity during a task that saw participants rewarded with payment, but in two different scenarios: a high and a low monetary reward condition.

“In the high monetary reward condition, participants earned higher than the expected reward; whereas in the low monetary condition, participants earned an average reward that was consistently lower than expected,” says Mizuno.

The brain images showed that before treatment with OROS-MPH, ADHD patients had lower than normal sensitivity to reward, as demonstrated by their abnormally low brain activity in two parts of the brain associated with reward processing—the nucleus accumbens and the thalamus—during testing under the low monetary reward scenario.

However, after three months of treatment with OROS-MPH, there was no difference in the activity of these brain areas in ADHD patients compared with the healthy controls under any of the reward conditions. Their sensitivity to reward had returned to normal, and the patients’ other ADHD symptoms also showed improvement.

Mizuno says that this study goes further than previous work. “We knew that acute MPH treatment improves reward processing in ADHD,” he explains. “Now we’ve revealed that decreased reward sensitivity and ADHD symptoms are improved by treatment for three months.”

Filed under brain activity fMRI ADHD methylphenidate dopamine osmotic release oral system neuroscience science

168 notes

Research Shows How Ritalin Affects Brains of Kids With ADHD

Ritalin activates specific areas of the brain in children with attention-deficit/hyperactivity disorder (ADHD), mimicking the brain activity of children without the condition, a new review says.

image

"This suggests that Ritalin does bring the brain [of a child with ADHD] back to the brain the typically developing kid has," said study author Constance Moore, associate director of the translational center for comparative neuroimaging at the University of Massachusetts Medical School.

Analyzing data from earlier studies that looked at how children’s brains were affected by doing certain tasks that are sometimes challenging for kids with ADHD, the researchers found that Ritalin (methylphenidate) was having a visible impact on three areas of the brain known to be associated with ADHD: the cortex, the cerebellum and the basal ganglia.

The study could be helpful in diagnosing and treating children with ADHD, Moore said. “It may be helpful to know that in certain children, Ritalin is having a physiological effect in the areas of the brain involved with attention and impulse control,” she said.

The research was published recently in the Harvard Review of Psychiatry.

Nine studies analyzed by the researchers used functional MRI to evaluate brain changes after children had taken a single dose of Ritalin. The children were involved in different types of tasks that tested their ability to focus and inhibit an impulse to act.

For example, to observe the brain’s reaction during a test of what is called “inhibitory control,” a child was told that every time he saw a zero show up on a screen, he should push the button on the right; every time he saw an X appear, he should push the left button. The children would then be asked to flip their responses, pushing the left button when they saw a zero.

"That’s hard to do," Moore said, "because you’ve developed the habit [of pushing the other button], so you have to suppress your impulse. If you do 20 zeros and keep pressing and then you see an X, most kids with ADHD will hit the wrong button."

In three out of five of the inhibitory control studies, Ritalin at least partially normalized brain activation in ADHD children.

To note how the brain reacted to a selective attention test, Moore said, children would first be asked, for example, what word they were seeing. The word would be “red,” and the color of the type also would be red. Then they would be shown the word “red,” but the color of the type would be green. In several studies, Ritalin affected activation in the frontal lobes during such inhibitory control tasks.

Most of the studies included in the review were performed in the United States or the United Kingdom. The majority of participants were adolescent boys, and all studies compared their results to healthy children of the same approximate age.

Because none of the studies looked at the correlation between ADHD symptoms and whether the child was taking Ritalin, there is no way to link the changes in brain activation with clinical improvement, Moore said. “It’s possible that kids who are not responsive to Ritalin may have brain changes too,” she said.

ADHD affects between 3 percent and 7 percent of school-aged children in the United States, according to the American Psychiatric Association. Boys are more likely to have ADHD than girls.

One expert was not surprised by the results.

"The review article shows there is a consensus of well-designed imaging studies showing that [Ritalin] has an impact on the frontal cortex of the brain, where we have long believed these patients have issues," said Dr. Andrew Adesman, chief of developmental and behavioral pediatrics at the Steven & Alexandra Cohen Children’s Medical Center of New York, in New Hyde Park. Adesman wondered if Ritalin may play a role in helping the brain mature.

"Their data provides partial support for that," he said. "But if anything, the medicine seems to help the brain look more normal and doesn’t seem to do anything bad to it."

(Source: consumer.healthday.com)

Filed under ADHD ritalin brain activity neuroimaging methylphenidate cortex neuroscience science

free counters